New acquisition for Fidia Farmaceutici of Abano Terme, world leader in research, development, production and marketing of innovative products mainly based on hyaluronic acid and its derivatives. This time the goal is the acquisition of pharmaceutical products from So.Se. Pharm srl, an Italian leader in the production and distribution of branded generic drugs, medical devices and supplements based in Pomezia (Rome) with a plant in Agnani.
Read more United Kingdom, Burnham promises fight against inflation and support for businesses
Ask the Sun
The questions are automatically suggested by 24Ore AI
based on the displayed content.
Fidia panoramic view of Fidia Farmaceutica Spa
The operation
In this way Fidia – which celebrates its 80th birthday – enriches its portfolio in the Cardiology and Urology areas with the brands Alamut, Antunes, Berny, Crotonil, Dicolev, Ferrogyn, Giachela, Nebiscon and Tadap, distributed and sold in Italy and in some non-EU countries.
This is the eighth financial operation carried out in the last 5 years, confirming the constant development path undertaken. The context is a growth plan through external lines that has seen the Group record investments of more than 300 million euros in acquisitions in the last five years, allowing an increase in Fidia’s turnover and EBITDA of 45%, from 371.2 to 538.3 million euros, and 45.8%, from 75.5 to 110 million euros, respectively, in the same period.
Read more Electoral law, hypothesis of gender parity to unlock the deadlock on preferences
The external growth path undertaken by the Group in recent years coincides with the start of direct management by Carlo Pizzocaro, who has been leading the company since 2016. Founded in 1946, Fidia Farmaceutici is an Italian company, world leader in research, development, production and marketing of innovative products based on hyaluronic acid and its derivatives (over 1,250 patents) in strategic areas such as joint care, skin care, eye care, specialty care and health & wellness care. Fidia has a production plant and Research and Development laboratories in Abano Terme (PD), where the company is headquartered, a specialized Research Unit in Noto and its own offices in Lombardy and Marche. The company distributes its products in over 120 countries.
Entrance of Fidia Farmaceutici Spa
The strategy
In the last decade, Fidia has oriented its development strategy towards operations aimed at expanding, integrating and diversifying the company portfolio. This plan started in 2016 with the acquisition of Biofarmitalia S.r.l, a company active in the development of transdermal patches for the treatment of osteoarticular pain, followed by the acquisition of Sooft Italia spa, an Italian leader in the ophthalmic sector. Since then, the company has continued with investments in complementary fields, including regenerative medicine, through the inclusion in the Group perimeter of Soluciones Bioregenerativas SL, a Spanish company specialized in the production of PRP, Platelet-Rich Plasma.
Read more Ansaldo returns to the US market with a contract for eight turbines
